| Q38782392 | A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study |
| Q30391932 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. |
| Q35706189 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update |
| Q38210344 | Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China |
| Q35422530 | Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. |
| Q41466695 | Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. |
| Q36492635 | Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis |
| Q38067130 | Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs |
| Q28084820 | Current and future antiviral drug therapies of hepatitis B chronic infection |
| Q38208628 | Current developments in nucleoside/nucleotide analogues for hepatitis B. |
| Q36154869 | DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model |
| Q38074646 | Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues |
| Q40502187 | Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. |
| Q40313106 | Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany |
| Q37564039 | Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. |
| Q36793870 | Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil. |
| Q34596639 | Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains |
| Q40957411 | Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure |
| Q40555175 | Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs |
| Q42151600 | Efficacy of tenofovir switch therapy for nucleos(t)ide-experienced patients with chronic hepatitis B. |
| Q38698073 | Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. |
| Q42208973 | Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis |
| Q40665887 | Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. |
| Q40967783 | Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. |
| Q36181175 | Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy |
| Q39213627 | Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains |
| Q64966428 | Hepatitis B virus treatment: Management of antiviral drug resistance. |
| Q38707903 | Hepatitis B: treatment choice and monitoring for response and resistance. |
| Q40667507 | Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B? |
| Q26752475 | KASL clinical practice guidelines: management of chronic hepatitis B |
| Q42278002 | Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine |
| Q34948124 | Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients |
| Q37696029 | Management of Antiviral Resistance in Chronic Hepatitis B. |
| Q26740323 | Management of HBV and HBV/HDV-Associated Liver Cirrhosis |
| Q27008984 | Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments |
| Q36145282 | Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies |
| Q37980893 | Management of treatment failure in chronic hepatitis B. |
| Q38219020 | Molecular diagnosis and treatment of drug-resistant hepatitis B virus |
| Q36325645 | On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B |
| Q38071396 | Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. |
| Q38295860 | Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? |
| Q36492959 | Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy |
| Q37229851 | Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade |
| Q41148991 | Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. |
| Q42175529 | Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients. |
| Q41929167 | RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg |
| Q36018658 | Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir |
| Q34847029 | Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis |
| Q41175515 | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. |
| Q41538789 | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. |
| Q42159733 | Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures |
| Q35639847 | Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir |
| Q40940597 | Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir |
| Q37097615 | The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy |
| Q42238958 | Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen |
| Q28072483 | Treatment for hepatitis B in patients with drug resistance |
| Q42287932 | Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine |
| Q38259535 | Update on hepatitis B virus infection |
| Q33857643 | Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir |